The therapeutic efficacy of IL-17 inhibitors in psoriatic arthritis, regardless of prior TNF inhibitor exposure, may contribute to the comparability between the drug retention of IL-17 inhibitors used for psoriasis aggravation and that of TNF inhibitors. This evidence concerns the gene IL17A and psoriasis.